For example, GLP-1 treatment was found to be neuroprotective in an in-vitro PD model through increasing PKA and PI3K pathway activity, reducing expression of apoptotic factors, and elevating expression of anti-apoptotic factors (Kopp et al. 2022). This evidence concerns the gene GLP1R and Parkinson disease.